knowledge -WSS

knowledge

author：hotspot 2025-09-28 16:34:40 - browse：837

Teleflex announced plans on Wednesday to acquire Palette Life Sciences, the maker of a slate of gel-based products treating urological disorders. The vascular device manufacturer will pay $600 million upfront, and plans to use Palette’s portfolio to treat more urinary tract and reproductive health conditions.

Palette will bring Teleflex an extra $56 million in sales, the company estimated in a press release. Teleflex develops a range of devices, but makes the most money from vascular products like catheters. The company offers just one urological treatment: the UroLift system to relieve an enlarged prostate. With Palette, it will gain five more treatments all built from hyaluronic acid, a stretchy material that’s meant to last longer in the human body.

Palette’s highest-revenue device is Barrigel, which helps protect the rectum from harsh radiation administered to prostate cancer patients. It eases symptoms like bladder inflammation, bleeding, and diarrhea. The device received FDA clearance in May 2022 through the 510(k) process, which allowed Palette to claim the product was equivalent to a rectal radiation protector sold by Boston Scientific. Boston Scientific has sold that device since 2018, when it acquired it by buying the startup Augmenix for $500 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： STAT Virtual Event: ASCO Recap, Live!

WSS

How faith leaders like me can help address America's obesity epidemic

What we need to know about Arena Bioworks

'Essentially witchcraft:' A former naturopath takes on the field

Cheap, fast test for Zika and dengue could cost just $1

General Catalyst, Summa Health deal will turn on physician buy

'Essentially witchcraft:' A former naturopath takes on the field

focus

knowledge

entertainment

Moonlake's readout produced a cash windfall. Risks remain

Lilly's Alzheimer's drug donanemab backed by FDA advisers

At least 13 dead in Texas as scorching temps continue

Medicare drug price negotiation’s day in court

New air purifier tech could be key to improving indoor air quality

Vertigo drug brings hope for rare neuron disorder, Niemann

Drug repurposing or repositioning? The language matters

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Deposition: Sackler embraced plan to conceal OxyContin’s strength

focus

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Statins may not be needed by millions of people, study suggests

California wildfire smoke linked to 52,000 early deaths, study says

Health care court cases: Humana, Sutter, Novant

Cybersecurity threat forces Lurie Children's to take systems offline

Cheap, fast test for Zika and dengue could cost just $1

Wikipedia

entertainment

knowledge

hotspot